Zabrina Watkins named diversity, equity, and inclusion director for Prime Therapeutics

March 28, 2022

Prime Therapeutics (Prime) recently named Zabrina Watkins its new diversity, equity and inclusion (DEI) director.

“At Prime, we’re committed to fostering a culture of inclusion, where everyone feels they can belong and thrive,” said Watkins. “This year we published our first DEI transparency report, highlighting steps we’ve taken toward enhancing workplace inclusion and pledging to continue this important journey,” Watkins added.

Effective March 1, 2022, Watkins assumed the role to build on current and future DEI initiatives for Prime. At Prime, Watkins previously served as co-chair for Prime’s Diversity & Inclusion (D&I) Council and now serves on its Alumni Board. Watkins also currently serves as a lead for Prime’s Black Professionals + Allies employee resource group.

“I am humbled to take on the role of DEI director,” Watkins said. “And I look forward to continuing to build upon the solid foundation and framework for strategies, programs and initiatives that reinforce Prime’s commitment to a more equitable and inclusive organization.”

Prime’s commitment to diversity, equity and inclusion is rooted in its collective values as a company and inseparable from Prime’s purpose and dedication to serving others. Going forward, Prime will further its mission to champion DEI awareness, outreach and events, engaging its employees on a journey toward making workplace inclusion a part of its DNA.

Related news

Stories

May 15, 2024

Prime/MRx experts share clinical insights for migraine treatment

Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs

Stories

May 14, 2024

Prime/MRx real-world GLP-1 persistence and adherence data published in Journal of Managed Care & Specialty Pharmacy

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended

Stories

May 14, 2024

Prime/MRx releases its first corporate social responsibility report

New report, an evolution of previous DEI reports, aims to demonstrate transparency and accountability for company’s corporate social responsibility journey